Body
| Antimalarial Drug | Protease Inhibitors | NRTI | NNRTI |
|---|---|---|---|
| Quinine | PIs: increase quinine levels | No available data | Efavirenz, Nevirapine: reduces quinine levels |
| Atovaquone/Proguanil | Lopinavir/Ritonavir, Atazanavir/Ritonavir: reduces atovaquone and proguanil levels | Efavirenz: reduces atovaquone and proguanil levels | |
| Mefloquine | Ritonavir: reduces ritonavir levels | Efavirenz, Nevirapine: reduces mefloquine levels | |
| Lumefantrine, Halofantrine | PIs: increase lumefantrine or halofantrine levels, which can prolong QT interval | Efavirenz, Nevirapine: increases lumefantrine or halofantrine levels, which can prolong QT interval | |
| Amodiaquine plus Artesunate | Efavirenz: increases amodiaquine concentration which can increase hepatic toxicity; do not co-administer | ||
| Chloroquine, Pyrimethamine, Sulfadoxine-Pyrimethamine | Ritonavir: alters anti-malarial drug metabolism, may increase chloroquine levels | ||
| Sulfadoxine-Pyrimethamine | Zidovudine: possibly increases risk of anemia | Nevirapine: possibly increases adverse skin or liver adverse reactions; do not start both drugs simultaneously | |
| Artemisinin | PIs: alter artemisinin metabolism | Nevirapine: may decrease artemisinin levels | |
| Dapsone | Saquinavir: alters dapsone metabolism | ||
| Key to Acronyms: NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; PI= protease inhibitor * Modified from: Flateau, C., G. Le Loup, et al. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis. 2011. 11(7);541-556. |
|||